Trial reportScientific reports2016
Plasma Proteomic Study in Pulmonary Arterial Hypertension Associated with Congenital Heart Diseases.
Trial report in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- Urinary CFHR2 as a Biomarker for Early Diagnosis and Disease Progression Prediction in Diabetic Kidney Disease.Current molecular medicine · 2026Article
- Group D of pulmonary arterial hypertension and its relationship to congenital heart disease: Is there a non-invasive way to predict the unpredictable?Global cardiology science & practice · 2025Review
- A bovine model of hypoxia-induced pulmonary hypertension reveals a gradient of immune and matrisome response with a complement signature found in circulation.American journal of physiology. Cell physiology · 2024Article
- The complement cascade in lung injury and disease.Respiratory research · 2024Review
- Proteome profiling of early gestational plasma reveals novel biomarkers of congenital heart disease.EMBO molecular medicine · 2023Article
- Pulmonary arterial hypertension associated with congenital heart disease: An omics study.Frontiers in cardiovascular medicine · 2023Review
- Biomarkers and key pathways in atrial fibrillation associated with mitral valve disease identified by multi-omics study.Annals of translational medicine · 2021Article
- Proteomic profiling identifies key differences between inter-stage infants with single ventricle heart disease and healthy controls.Translational research : the journal of laboratory and clinical medicine · 2021Article
- Integrative Omics to Characterize and Classify Pulmonary Vascular Disease.Clinics in chest medicine · 2021Review
- Proteomic analysis of pulmonary arterial hypertension.Therapeutic advances in chronic disease · 2021Review
- Screening and identification of serum biomarkers of osteoarticular tuberculosis based on mass spectrometry.Journal of clinical laboratory analysis · 2020Article
- Inflammation, immunity, and vascular remodeling in pulmonary hypertension; Evidence for complement involvement?Global cardiology science & practice · 2020Review
- Immunoglobulin-driven Complement Activation Regulates Proinflammatory Remodeling in Pulmonary Hypertension.American journal of respiratory and critical care medicine · 2020Article
- Corrective surgery alters plasma protein profiling in congenital heart diseases and clinical perspectives.American journal of translational research · 2020Article
- Increased circulating levels of tumor necrosis factor-like cytokine 1A and decoy receptor 3 correlate with SYNTAX score in patients undergoing coronary surgery.The Journal of international medical research · 2018Article
- Plasma protein profiling in patients undergoing coronary artery bypass grafting surgery and clinical significance.Oncotarget · 2017Article
- Chloride Channels are Involved in the Development of Atrial Fibrillation - A Transcriptomic and proteomic Study.Scientific reports · 2017Article
- Remote Sensing between Liver and Intestine: Importance of Microbial Metabolites.Current pharmacology reports · 2017Article
- Serum biomarker analysis at the protein level on pulmonary hypertension secondary to old anterior myocardial infarction.Pulmonary circulationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary arterial hypertension associated with congenital heart disease (CHD-PAH) has serious consequence and plasma protein profiles in CHD-PAH are unknown. We aimed to reveal the differential plasma proteins in 272 CHD patients with or without PAH. Various types of CHD-PAH were studied. Differential plasma proteins were first detected by iTRAQ proteomic technology and those with significant clinical relevance were selected for further ELISA validation in new cohort of patients. Among the 190 differential plasma proteins detected by iTRAQ, carbamoyl-phosphate synthetase I (CPSI, related to urea cycle and endogenous nitric oxide production) and complement factor H-related protein 2 (CFHR2, related to complement system and coagulant mechanism) were selected for further ELISA validation in new cohort of 152 patients. Both CPSI and CFHR2 were down-regulated with decreased plasma levels (p < 0.01). Thus, we for the first time in CHD-PAH patients identified a large number of differential plasma proteins. The decreased CPSI expression in CHD-PAH patients may reveal a mechanism related to endogenous nitric oxide and the decrease of CFHR2 protein may demonstrate the deficiency of the immune system and coagulation mechanism. The findings may open a new direction for translational medicine in CHD-PAH with regard to the diagnosis and progress of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.